Nanosized Trojan horses created from a patient’s own immune cells have successfully treated inflammation by overcoming the body’s complex defense mechanisms, perhaps leading to broader applications for treating diseases characterized by inflammation, such as cancer and cardiovascular diseases.
An international team, led by researchers at Houston Methodist Research Institute, described the creation of nanoparticles called leukosomes and evaluated their ability to treat localized inflammation in the May 23 issue of Nature Materials (early online).
Recent approaches to treating inflammatory diseases have been unsuccessful because an already overactive immune system treats simple nanoparticles as foreign invaders and clears them from the body, preventing them from reaching their target.
“A better approach for building effective drug delivery platforms is to find inspiration for their design in the composition of the immune cells of our body,” said Ennio Tasciotti, Ph.D., director of the Center for Biomimetic Medicine at Houston Methodist Research Institute and the paper’s senior author. “Immune cells such as leukocytes freely circulate in blood vessels, recognize inflammation, and accumulate in inflamed tissues. They do so by using special receptors and ligands on their surface. We purified leukocytes from a patient, then integrated their special ligands and receptors into the leukosome surface. Using the body’s own materials, we built a drug delivery system camouflaged as our own body’s defense system—thus the Trojan horse.”
In its normal form, acute inflammation is a necessary and beneficial part of the body’s defense against infection. However, under certain conditions, inflammation can turn from a friend to a vicious foe, damaging or destroying healthy cells. This is the case for autoimmune disorders such as rheumatoid arthritis, lupus and inflammatory bowel disease, or in illnesses such as Alzheimer’s, cancer, cardiovascular disease and Type 2 diabetes.
Leukosomes are able to target inflamed tissues because they retain the same surface properties of the immune cell membranes from which they are made. To evaluate leukosomes’ effectiveness as drug carriers, Tasciotti and his colleagues created vesicles from mouse leukocytes and filled them with dexamethasone (DXM), an anti-inflammatory agent.
“We used ‘personalized’ DXM-loaded leukosomes to treat inflammation in mice,” Tasciotti said. “After administering the leukosomes, we observed their attachment to the surface of blood vessels surrounding the inflamed tissue, and they selectively delivered DXM to the affected cells.”
The treated mice showed definite signs of improvement, including resolution of the inflammation, a significant reduction in tissue thickness, and a reversal of the immune response that is commonly seen in inflammation.
The success of the team’s initial leukosome trial is encouraging, Tasciotti said, and suggests that membranes purified from any other cell types could also be used as biomimetic nanocarriers to treat other diseases.
“By combining cell biology with nanotechnology, we can create valuable medical tools that work within, and not around, the laws of nature,” he said.
Learn more: Nanoscale trojan horses treat inflammation
The Latest on: Treating inflammation
via Google News
The Latest on: Treating inflammation
- India Allows Use Of Low-Cost Steroid To Treat Coronavirus Patientson June 27, 2020 at 2:00 am
The government on Saturday allowed the use of the steroid drug dexamethasone as an alternative to methylprednisolone to treat coronavirus patients with moderate and severe symptoms. The World Health ...
- Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejectionon June 26, 2020 at 3:14 pm
The FDA has rejected an investigational AbbVie drug for the “wet” form of age-related macular degeneration, dealing a setback to the company’s bid to ...
- An Update on COVID-19 Treatments Being Researched in Coloradoon June 26, 2020 at 1:45 pm
How it works: Ruxolitinib—a drug used to treat myelofibrosis, a rare type of bone marrow cancer—could also potentially inhibit the inflammatory immune response that occurs in people with severe ...
- Researchers Examine How COVID-19 Virus May Increase Lung Inflammationon June 26, 2020 at 7:41 am
A team from the Center for Advanced Pain Studies pinpointed a potential strategy for counteracting the acceleration of COVID-19 while studying if the pulmonary issues tied to the virus could originate ...
- Ocular Inflammation Treatment Market 2020 Top Manufacturers, Analysis, Industry Size, Future Trends and Industry Growth Research Report 2025on June 24, 2020 at 5:00 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Ocular Inflammation Treatment Market” report studies the market in-depth and provides an all-encompassing ...
- People with inflammatory bowel disease might be at higher risk for dementia, study findson June 23, 2020 at 3:46 pm
Inflammation is connected to an increased risk of stroke as well, which can lead to the vascular dementia that cuts off blood from the brain and thus cognitive function. In addition, research found ...
- BRIEF-Avicanna Announces Co-Development Of Cannabinoid-Based Formulation For Treatment Of Covid-19 Related Lung Inflammationon June 23, 2020 at 9:49 am
DEVELOPMENT OF A CANNABINOID-BASED FORMULATION FOR TREATMENT OF COVID-19 RELATED LUNG INFLAMMATION WITH SUPPORT FROM THE MITACS ACCELERATE PROGRAM * AVICANNA - CO, DR. CHRISTINE ALLEN’S RESEARCH GROUP ...
- Coronavirus Treatment: Gilead Starting Trial Of Spray Version Of Remdesivir, Anti-Inflammatory Comboson June 22, 2020 at 8:36 am
Gilead's chairman and CEO says treating coronavirus in its early stages will be key in overcoming the pandemic.
- Repurposed drug shows promise for treating COVID-19 inflammationon June 18, 2020 at 2:44 pm
Yale clinicians report promising results after treating COVID-19 with the drug tocilizumab, which is known to reduce inflammation in chemotherapy patients.
- Could Good Oral Health Be the Key to Treating Inflammatory Bowel Disease?on June 17, 2020 at 5:00 am
Researchers from the University of Michigan Medical and Dental School discovered that inflammatory bowel disease may be the latest condition made worse by poor oral health.
via Bing News